GSK makes another ADC deal, this time with BioNTech’s partner DualityBionews2024-12-04T08:28:36+00:00December 4th, 2024|Endpoints News|
Coherus makes final, $483M pivot away from biosimilarsnews2024-12-03T18:44:02+00:00December 3rd, 2024|Endpoints News|
Ipsen secures rights to T cell engager in $610M pact with Biomunexnews2024-12-03T16:27:53+00:00December 3rd, 2024|Endpoints News|
Relay licenses lirafugratinib to Elevar for $75Mnews2024-12-03T16:12:58+00:00December 3rd, 2024|Endpoints News|
Takeda to pay $200M for rights to anemia drug from Kerosnews2024-12-03T12:00:51+00:00December 3rd, 2024|Endpoints News|
Gilead makes another ADC move, inking up to $415M pact with Tubulisnews2024-12-03T12:00:44+00:00December 3rd, 2024|Endpoints News|
Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticalsnews2024-12-03T11:30:57+00:00December 3rd, 2024|Endpoints News|
Olema, Novartis ink another agreement, this time for a late-stage breast cancer trialnews2024-12-02T15:58:33+00:00December 2nd, 2024|Endpoints News|
Novartis pays $1B upfront for PTC’s Phase 2 Huntington’s drugnews2024-12-02T12:35:53+00:00December 2nd, 2024|Endpoints News|
Acadia snaps up an essential tremor drug after field’s summer setbacksnews2024-11-27T12:22:20+00:00November 27th, 2024|Endpoints News|
